AZINUS-250 Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
AZINUS-250
Azithromycin 250mg
AZINUS-250 is a broad-spectrum bactericidal antimicrobial agent exhibiting enhanced pharmacokinetic tissue penetration against susceptible gram-positive and gram-negative pathogens.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Inhibits bacterial DNA gyrase (type II topoisomerase) and topoisomerase IV enzymes required for bacterial DNA replication, transcription, and repair.
Adult: One dose once or twice daily depending on infectious severity. Complete full course to prevent antimicrobial resistance.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C in a dry place. Protect from moisture and direct sunlight.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
AZINUS-250 features Azithromycin 250mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Apply for Exclusive Marketing Rights of AZINUS-250
Check vacant territory availability in your state or district. Enjoy full marketing kit support, visual aids, and guaranteed zero competitor supply.
Questions Regarding AZINUS-250
What is the therapeutic indication and composition of AZINUS-250?
AZINUS-250 contains Azithromycin 250mg indicated for Lower Respiratory Tract Infections as formulated by Sygnus Biotech.
What packaging presentations are available for AZINUS-250?
AZINUS-250 is supplied in tamper-evident 10 x 10 Alu-Alu / Blister Pack, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for AZINUS-250?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for AZINUS-250 along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
AZINUS-250 is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Tablet
View all Tablet →
DAIBET-G2 V
Glimepiride 2mg + Metformin Hydrochloride 500mg + Voglibose 0.2mg Bilayered
